Altria's Underlying Trends Intact in First Quarter
We view this wide-moat firm as undervalued.
Underlying trends in the U.S. cigarette industry appear to be intact following Altria's (MO) first quarter results, which included very strong shipment numbers, with comparability affected by a number of technical issues. Aside from adjusting for the timing of some of the company's shipments that were brought forward into the first quarter, we are making only modest tweaks to our estimates for the remainder of the year and our longer-term outlook is unchanged. We are reiterating our wide moat rating and $54 fair value estimate. As of May 4, Altria continues to appear undervalued, although we think there is more upside to Imperial Tobacco and Philip Morris is the more defensive, high-quality pick of the group.
Reported cigarette shipment volume was up by 6% in the first quarter, although when adjusting for trade inventory movements, significant pantry stocking by consumers, and an extra trading day, volumes fell by 3.5%. This was in line with recent trends, but Altria lost 60 basis points of retail volume share in cigarettes over the same period a year ago, which management attributed to older smokers returning to the cigarette category from vaping into the discount segment. It seems likely that Altria's share could continue to decline over the next year or so, particularly if the U.S. enters a sustained recession. Management reiterated its guidance of industry volume decline rate of 4% to 6% this year, although it abandoned all other guidance for the year.
The spread of COVID-19 caused some disruption during the quarter, with the Richmond, VA manufacturing facility being temporarily closed. That plant has now been reopened and we do not anticipate any distribution disruption. The pandemic has also caused management to slow the planned rollout of iQOS in the U.S. Our view is unchanged in that adoption is likely to be very slow, especially in light of the risk of recession.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Philip Gorham does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.